43742-1631 NDC - HYDRATION COMPLEX (BETA VULGARIS, BOLDO, CARDUUS BENEDICTUS, CHELIDONIUM MAJUS, COFFEA TOSTA, EQUISETUM ARVENSE, PETROSELINUM SATIVUM, TARAXACUM OFFICINALE, HYPERICUM PERFORATUM, GINKGO BILOBA, KALI MURIATICUM, KALI PHOSPHORICUM, KALI SULPHURICUM, GERMANIUM SESQUIOXIDE, SILICEA, CALCAREA FLUORICA, CALCAREA PHOSPHORICA)

Drug Information

Product NDC: 43742-1631
Proprietary Name: Hydration Complex
Non Proprietary Name: Beta Vulgaris, Boldo, Carduus Benedictus, Chelidonium Majus, Coffea Tosta, Equisetum Arvense, Petroselinum Sativum, Taraxacum Officinale, Hypericum Perforatum, Ginkgo Biloba, Kali Muriaticum, Kali Phosphoricum, Kali Sulphuricum, Germanium Sesquioxide, Silicea, Calcarea Fluorica, Calcarea Phosphorica
Active Ingredient(s): 1 [hp_X]/mL BETA VULGARIS; 8 [hp_X]/mL CALCIUM FLUORIDE; 1 [hp_X]/mL CENTAUREA BENEDICTA; 1 [hp_X]/mL CHELIDONIUM MAJUS; 1 [hp_X]/mL COFFEA ARABICA SEED, ROASTED; 6 [hp_X]/mL DIBASIC POTASSIUM PHOSPHATE; 1 [hp_X]/mL EQUISETUM ARVENSE TOP; 8 [hp_X]/mL GERMANIUM SESQUIOXIDE; 6 [hp_X]/mL GINKGO; 3 [hp_X]/mL HYPERICUM PERFORATUM WHOLE; 1 [hp_X]/mL PETROSELINUM CRISPUM; 1 [hp_X]/mL PEUMUS BOLDUS LEAF; 6 [hp_X]/mL POTASSIUM CHLORIDE; 6 [hp_X]/mL POTASSIUM SULFATE; 8 [hp_X]/mL SILICON DIOXIDE; 1 [hp_X]/mL TARAXACUM OFFICINALE; 8 [hp_X]/mL TRIBASIC CALCIUM PHOSPHATE
Administration Route(s): ORAL
Dosage Form(s): LIQUID
Pharmacy Class(es): Blood Coagulation Factor [EPC]; Calcium [CS]; Cations; Divalent [CS]; Increased Coagulation Factor Activity [PE]; Increased Large Intestinal Motility [PE]; Increased Large Intestinal Motility [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Osmotic Activity [MoA]; Osmotic Activity [MoA]; Osmotic Laxative [EPC]; Osmotic Laxative [EPC]; Potassium Compounds [CS]; Potassium Compounds [CS]; Potassium Salt [EPC]; Potassium Salt [EPC]

Labeler Information

Field Name	Field Value
Labeler Name:	Deseret Biologicals, Inc.
Product Type:	HUMAN OTC DRUG
FDA Application Number:
Marketing Category:	UNAPPROVED HOMEOPATHIC
Start Marketing Date:	3/24/2020
End Marketing Date:	5/26/2026

Package Information

No.	Package Code	Package Description	Billing Unit
1	43742-1631-1	60 mL in 1 BOTTLE, DROPPER (43742-1631-1)

NDC Record

Field Name	Field Value	Definition
PRODUCT NDC	43742-1631	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAME	HUMAN OTC DRUG	Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAME	Hydration Complex	The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAME	Beta Vulgaris, Boldo, Carduus Benedictus, Chelidonium Majus, Coffea Tosta, Equisetum Arvense, Petroselinum Sativum, Taraxacum Officinale, Hypericum Perforatum, Ginkgo Biloba, Kali Muriaticum, Kali Phosphoricum, Kali Sulphuricum, Germanium Sesquioxide, Silicea, Calcarea Fluorica, Calcarea Phosphorica	The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAME	LIQUID	The translation of the dosage form Code submitted by the firm.
ROUTE NAME	ORAL	The translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE	3/24/2020	This is the date that the labeler indicates was the start of its marketing of the drug product.
END MARKETING DATE	5/26/2026	This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
MARKETING CATEGORY NAME	UNAPPROVED HOMEOPATHIC	Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
LABELER NAME	Deseret Biologicals, Inc.	Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAME	BETA VULGARIS; CALCIUM FLUORIDE; CENTAUREA BENEDICTA; CHELIDONIUM MAJUS; COFFEA ARABICA SEED, ROASTED; DIBASIC POTASSIUM PHOSPHATE; EQUISETUM ARVENSE TOP; GERMANIUM SESQUIOXIDE; GINKGO; HYPERICUM PERFORATUM WHOLE; PETROSELINUM CRISPUM; PEUMUS BOLDUS LEAF; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SILICON DIOXIDE; TARAXACUM OFFICINALE; TRIBASIC CALCIUM PHOSPHATE	An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH	1; 8; 1; 1; 1; 6; 1; 8; 6; 3; 1; 1; 6; 6; 8; 1; 8
ACTIVE INGRED UNIT	[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL
PHARM CLASSES	Blood Coagulation Factor [EPC], Calcium [CS], Cations, Divalent [CS], Increased Coagulation Factor Activity [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Potassium Compounds [CS], Potassium Compounds [CS], Potassium Salt [EPC], Potassium Salt [EPC]

Drug Information

Labeler Information

Package Information

NDC Record

Download Record